Page 24 - Imprint-magazine june-Issue

Business News

Bharat Biotech, GCVC sign MoU to produce drug

substance for Covaxin

Bharat Biotech shall provide the technology for the production of the drug sub-
stance for Covaxin and GBRC will act as an advisor and mentor and will
facilitate the technology transfer from Bharat Biotech

Hester Biosciences on 27th (GCVC) for contract GCVC comprises Gujarat Bio-
May 2021 said a memorandum manufacturing the drug technology Research Centre
of understanding (MoU) has substance for Covaxin. (GBRC), Hester Biosciences and
been signed between vaccine Omnibrx Biotechnologies Pvt
maker Bharat Biotech and Gu- Ltd
jarat Covid Vaccine Consortium The entire process Read More

is facilitated by the
Department of

Biotechnology

IIL to produce drug substance for Bharat Biotech’s

Covaxin

First batch to be dispatched to Bharat Biotech by July

To further increase the IIL has announced its plans to K Anand Kumar, Managing
COVID-19 vaccine begin the production of drug Director, IILs in a release said
manufacturing capacity, Bharat substance meant for COVID-19 the firm is expected to produce
Biotech partnered with Indian vaccine Covaxin from June 15, the drug substance initially for
Immunologicals Ltd (IIL) to and despatch the first batch to two to three million doses per
make the drug substance for Bharat Biotech by July. month.
Covaxin. Read More

Zydus Cadila gets USFDA approval for generic drug

The company has received approval from the US Food and Drug
Administration (USFDA) to market in the US its generic version in strengths of
1 mg,

The drug will be Drug firm Zydus Cadila on certain type of mental
manufactured at Saturday said it has received ailments.
final approval from the US
the group’s formula- health regulator to market Zydus Cadila said, the company

tion manufacturing Fluphenazine Hydrochloride has received approval from the
US Food and Drug
tablets, used in the treatment
facility at the SEZ, of Administration (USFDA)
Ahmedabad Read More

22 JUNE-2021